We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
Back
11-02-2019

Neuraxpharm Group makes a step forward by rebranding its subsidiary also in Spain


-PRESS RELEASE-

Spanish pharmaceutical Qualigen is now called Neuraxpharm

  • This rebranding completes the Spanish’s company’s integration into the European group of the same name
  • Neuraxpharm strengthens its international growth and boosts its position as a leading European specialist in the treatment of Central Nervous System (CNS) disorders


February 7, 2019.
 Qualigen, the Spanish pharmaceutical, is changing its name to Neuraxpharm in the final stage of its integration into the European group of the same name and will add the values which have guided the company over its ten years to the group’s 30 years’ experience.

This rebranding strengthens the company’s international growth and consolidates its position as a leading European specialist in the treatment of Central Nervous System (CNS) disorders.

Neuraxpharm is a European pharmaceutical group with direct presence in Spain, Germany, France, Italy, Poland and, after its recent takeover of Farmax, the Czech Republic, Slovakia, and Hungary which sees the group expand its presence in Central and Eastern Europe. Neuraxpharm has over 700 employees and sells its products in more than fifty countries. The company specialises in the research, development, production and sale of differentiated medication, active ingredients, and dosage forms for the Central Nervous System, which are important assets for both patients and health professionals. 

It currently has a range of more than 130 products and 550 dosage forms in the main reference pharmaceuticals and nutraceuticals in the treatment of neurological and psychiatric disorders such as schizophrenia, depression, anxiety, neuropathic pain, Alzheimer’s, epilepsy and Parkinson’s, amongst others.

Javier Mercadé, General Manager of Neuraxpharm Spain, commented: "Joining this leading European group enables our company to further strengthen its leading position in CNS in Spain. Neuraxpharm will maintain its focus on innovation and the quality of its products and services to continue to provide patients suffering from central nervous system disorders a complete spectrum of treatment options to improve their health and quality of life".

Neuraxpharm Spain S.L. is headquartered in Sant Joan Despi (Barcelona). The group has two production plants in Spain and a team of over 400 employees, including 80 R&D specialists. Since its foundation in 2008, the company has launched more than 40 molecules for the treatment of CNS pathologies with both branded and generic pharmaceuticals. It continues to develop its range with a growing portfolio of drugs for other CNS indications and launches a new product every month. 

Neuraxpharm is ranked in Category A “Very Good” in the Spanish Ministry of Industry, Trade, and Tourism’s PROFARMA plan, which recognises the industry’s commitment to research and production in Spain. The company recorded growth of approximately 12% in 2018. 76% of sales were in products for the treatment of Central Nervous System disorders, where it leads the market in antipsychotics. 

www.neuraxpharm.es



Please find below the press release in English and Spanish: